Combination of anlotinib and albumin-bound paclitaxel in 2nd line and above treatment of advanced gastric cancer: A retrospective study

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 16, Issue 4

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

All Articles published online

Item

Count

PDF

HTML

195

Figures (1-3)

Tables (1-3)

Sum=419

Publishing Process of This Article

Item

Count

Browse

Download

Sum=65

Apr 24, 2025 (publication date) through Apr 25, 2025

Times Cited of This Article

Journal Information of This Article

Publication Name

World Journal of Clinical Oncology

ISSN

2218-4333

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Retrospective Study

World J Clin Oncol. Apr 24, 2025; 16(4): 102199
Published online Apr 24, 2025. doi: 10.5306/wjco.v16.i4.102199

Table 2 Clinical efficacy of anlotinib combined with nab-ptx in second-line or above treatment for advanced gastric cancer

OS: Overall survival; PFS: Progression-free survival.

Citation: Liu WM, Liu YR, Peng Y, Tang J, Li XB. Combination of anlotinib and albumin-bound paclitaxel in 2^nd line and above treatment of advanced gastric cancer: A retrospective study. World J Clin Oncol 2025; 16(4): 102199
URL: https://www.wjgnet.com/2218-4333/full/v16/i4/102199.htm
DOI: https://dx.doi.org/10.5306/wjco.v16.i4.102199